{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:19:11Z","timestamp":1787624351704,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05427-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:14:19Z","timestamp":1780546459000},"page":"17959-17969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a prognostic nomogram for predicting the progression risk of HCC after lenvatinib therapy"],"prefix":"10.1007","volume":"399","author":[{"given":"Chen","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-5281","authenticated-orcid":false,"given":"Xiuhua","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"5427_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CEJ.0000000000000428","volume":"27","author":"A Baecker","year":"2018","unstructured":"Baecker A, Liu X, La Vecchia C, Zhang ZF (2018) Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 27(3):205\u201312","journal-title":"Eur J Cancer Prev"},{"key":"5427_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.919824","volume":"12","author":"S Bai","year":"2022","unstructured":"Bai S, Hu L, Liu J, Sun M, Sun Y, Xue F (2022) Prognostic nomograms combined adjuvant Lenvatinib for Hepatitis B Virus-related hepatocellular carcinoma with microvascular invasion after radical resection. Front Oncol 12:919824","journal-title":"Front Oncol"},{"issue":"1","key":"5427_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2019.08.032","volume":"72","author":"G Berardi","year":"2020","unstructured":"Berardi G, Morise Z, Sposito C, Igarashi K, Panetta V, Simonelli I et al (2020) Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol 72(1):75\u201384","journal-title":"J Hepatol"},{"issue":"3","key":"5427_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejso.2021.09.012","volume":"48","author":"BR Beumer","year":"2022","unstructured":"Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, Ij JNM et al (2022) Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur J Surg Oncol 48(3):492\u20139","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"5427_CR5","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1002\/hep.29662","volume":"67","author":"M Borzio","year":"2018","unstructured":"Borzio M, Dionigi E, Rossini A, Marignani M, Sacco R, De Sio I et al (2018) External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study. Hepatology 67(6):2215\u20132225","journal-title":"Hepatology"},{"key":"5427_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23625","author":"A Buttell","year":"2023","unstructured":"Buttell A, Qiu W (2023) The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog. https:\/\/doi.org\/10.1002\/mc.23625","journal-title":"Mol Carcinog"},{"issue":"21","key":"5427_CR7","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252\u20137259","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5427_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12911-019-1014-6","volume":"20","author":"AM Carrington","year":"2020","unstructured":"Carrington AM, Fieguth PW, Qazi H, Holzinger A, Chen HH, Mayr F et al (2020) A new concordant partial AUC and partial c statistic for imbalanced data in the evaluation of machine learning algorithms. BMC Med Inform Decis Mak 20(1):4","journal-title":"BMC Med Inform Decis Mak"},{"issue":"2","key":"5427_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cgh.2013.10.038","volume":"13","author":"R Chaiteerakij","year":"2015","unstructured":"Chaiteerakij R, Addissie BD, Roberts LR (2015) Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol 13(2):237\u2013245","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5427_CR10","volume":"19","author":"S Chen","year":"2026","unstructured":"Chen S, Yang Z, Yang L (2026) Development and vlidation of a nomogram for predicting poor outcome in spontaneous cervical artery dissection. Int J Gen Med 19:556836","journal-title":"Int J Gen Med"},{"issue":"12","key":"5427_CR11","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1007\/s00330-023-09830-7","volume":"33","author":"S Cheng","year":"2023","unstructured":"Cheng S, Hu G, Jin Z, Wang Z, Xue H (2023) CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus. Eur Radiol 33(12):8715\u20138726","journal-title":"Eur Radiol"},{"issue":"5","key":"5427_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1159\/000508901","volume":"9","author":"J Cheon","year":"2020","unstructured":"Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM et al (2020) Real-world efficacy and safety of Lenvatinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Liver Cancer 9(5):613\u2013624","journal-title":"Liver Cancer"},{"issue":"1","key":"5427_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000369688","volume":"35","author":"SX Cui","year":"2015","unstructured":"Cui SX, Zhang YS, Chu JH, Song ZY, Qu XJ (2015) Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells. Cell Physiol Biochem 35(1):201\u2013212","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"5427_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1572-0241.2006.00443.x","volume":"101","author":"F Farinati","year":"2006","unstructured":"Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C et al (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101(3):524\u2013532","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"5427_CR15","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/liv.14223","volume":"39","author":"PR Galle","year":"2019","unstructured":"Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S et al (2019) Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 39(12):2214\u201329","journal-title":"Liver Int"},{"issue":"2","key":"5427_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","volume":"25","author":"MS Grandhi","year":"2016","unstructured":"Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM (2016) Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol 25(2):74\u201385","journal-title":"Surg Oncol"},{"issue":"1d","key":"5427_CR17","volume":"22","author":"Y He","year":"2023","unstructured":"He Y, Luo L, Shan R, Qian J, Cui L, Wu Z et al (2023) Development and validation of a nomogram for predicting postoperative early relapse and survival in hepatocellular carcinoma. J Natl Compr Canc Netn 22(1d):e237069","journal-title":"J Natl Compr Canc Netn"},{"issue":"6","key":"5427_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000517393","volume":"10","author":"YW Hung","year":"2021","unstructured":"Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC et al (2021) Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria. Liver Cancer 10(6):629\u201340","journal-title":"Liver Cancer"},{"issue":"10","key":"5427_CR19","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1111\/hepr.12451","volume":"45","author":"T Kamiyama","year":"2015","unstructured":"Kamiyama T, Yokoo H, Kakisaka T, Orimo T, Wakayama K, Kamachi H et al (2015) Multiplication of alpha-fetoprotein and protein induced by vitamin K absence-II is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy. Hepatol Res 45(10):E21-31","journal-title":"Hepatol Res"},{"issue":"6","key":"5427_CR20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00268-013-1966-0","volume":"37","author":"JM Kim","year":"2013","unstructured":"Kim JM, Hyuck C, Kwon D, Joh JW, Lee JH, Paik SW et al (2013) Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg 37(6):1371\u20138","journal-title":"World J Surg"},{"issue":"8","key":"5427_CR21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s11605-018-04074-z","volume":"23","author":"JM Kim","year":"2019","unstructured":"Kim JM, Kwon CHD, Joh JW, Yoo H, Kim K, Sinn DH et al (2019) Nomograms in hepatectomy patients with Hepatitis B Virus-related hepatocellular carcinoma. J Gastrointest Surg 23(8):1559\u201367","journal-title":"J Gastrointest Surg"},{"key":"5427_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-52","volume":"13","author":"A Kinoshita","year":"2013","unstructured":"Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K et al (2013) The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 13:52","journal-title":"BMC Cancer"},{"key":"5427_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123156","author":"YH Kuo","year":"2023","unstructured":"Kuo YH, Huang TH, Yen YH, Lu SN, Wang JH, Hung CH et al (2023) Nomogram to predict the long-term overall survival of early-stage hepatocellular carcinoma after radiofrequency ablation. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15123156","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5427_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52\u201360","journal-title":"Semin Liver Dis"},{"issue":"10","key":"5427_CR25","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1093\/oncolo\/oyad107","volume":"28","author":"X Li","year":"2023","unstructured":"Li X, Ding X, Liu M, Wang J, Li W, Chen J (2023) Development of a multivariate prognostic model for lenvatinib treatment in hepatocellular carcinoma. Oncologist 28(10):e942\u2013e949","journal-title":"Oncologist"},{"key":"5427_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109771","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y et al (2023) Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: multicenter retrospective study. Front Immunol 14:1109771","journal-title":"Front Immunol"},{"issue":"1","key":"5427_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"5427_CR28","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y et al (2018) Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 7(6):2641\u201353","journal-title":"Cancer Med"},{"issue":"2","key":"5427_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","volume":"19","author":"KA McGlynn","year":"2015","unstructured":"McGlynn KA, Petrick JL, London WT (2015) Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19(2):223\u2013238","journal-title":"Clin Liver Dis"},{"key":"5427_CR30","unstructured":"National Cancer Institute (n.d.) Protocol development. Cancer therapy evaluation program. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm[cited 2023 March 21]"},{"issue":"8","key":"5427_CR31","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z","volume":"64","author":"F Nomura","year":"1989","unstructured":"Nomura F, Ohnishi K, Tanabe Y (1989) Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 64(8):1700\u20131707","journal-title":"Cancer"},{"issue":"2","key":"5427_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/liv.12274","volume":"34","author":"H Park","year":"2014","unstructured":"Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY et al (2014) Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver Int 34(2):313\u2013321","journal-title":"Liver Int"},{"issue":"1","key":"5427_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s15010-019-01345-y","volume":"48","author":"E Sagnelli","year":"2020","unstructured":"Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C (2020) Epidemiological and etiological variations in hepatocellular carcinoma. Infection 48(1):7\u201317","journal-title":"Infection"},{"key":"5427_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2613492","volume":"2023","author":"L Song","year":"2023","unstructured":"Song L, Su X, Lu Y, Hua D, Gao Z (2023) An inflammation-associated prognosis model for hepatocellular carcinoma based on adenylate uridylate- (AU-) rich element genes. Mediators Inflamm 2023:2613492","journal-title":"Mediators Inflamm"},{"issue":"10","key":"5427_CR35","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9","volume":"73","author":"T Suehiro","year":"1994","unstructured":"Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T (1994) Protein induced by Vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 73(10):2464\u20132471","journal-title":"Cancer"},{"issue":"3","key":"5427_CR36","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u201349","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"5427_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261(5):947\u2013955","journal-title":"Ann Surg"},{"issue":"7","key":"5427_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/hepr.13505","volume":"50","author":"T Terashima","year":"2020","unstructured":"Terashima T, Yamashita T, Takata N, Toyama T, Shimakami T, Takatori H et al (2020) Comparative analysis of liver functional reserve during Lenvatinib and Sorafenib for advanced hepatocellular carcinoma. Hepatol Res 50(7):871\u2013884","journal-title":"Hepatol Res"},{"issue":"1","key":"5427_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-024-00626-2","volume":"11","author":"C Wang","year":"2024","unstructured":"Wang C, Fang J, Jiang T et al (2024) Development and validation of a prognostic nomogram model in locally advanced NSCLC based on metabolic features of PET\/CT and hematological inflammatory indicators. EJNMMI Phys 11(1):24","journal-title":"EJNMMI Phys"},{"issue":"20","key":"5427_CR40","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20134","journal-title":"JAMA"},{"key":"5427_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K et al (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18","journal-title":"Vasc Cell"},{"key":"5427_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726213","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J (2021) Progression of prothrombin induced by Vitamin K Absence-II in hepatocellular carcinoma. Front Oncol 11:726213","journal-title":"Front Oncol"},{"issue":"4","key":"5427_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W et al (2023) Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 20(4):203\u2013222","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"5427_CR44","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i11.112981","volume":"17","author":"ZY Yao","year":"2025","unstructured":"Yao ZY, Bao G, Li GC et al (2025) Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: a novel model. World J Gastrointest Oncol 17(11):112981","journal-title":"World J Gastrointest Oncol"},{"key":"5427_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1640469","volume":"12","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Chen YF, Liu XM et al (2025) Analysis of risk factors and prognostic prediction in advanced colorectal cancer undergoing immunotherapy combined with targeted therapy. Front Med 12:1640469","journal-title":"Front Med"},{"issue":"10","key":"5427_CR46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/jcph.2312","volume":"63","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wei Z, Zheng Y (2023) Disproportionality analysis of Lenvatinib-caused gastrointestinal perforation in cancer patients: A pharmacovigilance analysis based on the US Food and Drug Administration adverse event reporting system. J Clin Pharmacol 63(10):1133\u20131140","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"5427_CR47","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-21-3275","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z et al (2022) Alpha-fetoprotein as a potential surrogate biomarker for Atezolizumab + Bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res 28(16):3537\u201345","journal-title":"Clin Cancer Res"},{"key":"5427_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6645476","volume":"2023","author":"J Zhu","year":"2023","unstructured":"Zhu J, Kuang J, Yang Y, Zhang L, Leng B, She R et al (2023) A prognostic model based on NSUN3 was established to evaluate the prognosis and response to immunotherapy in liver hepatocellular carcinoma. Mediators Inflamm 2023:6645476","journal-title":"Mediators Inflamm"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05427-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05427-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05427-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:24:29Z","timestamp":1787621069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05427-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5427"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05427-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was conducted in accordance with the declaration of Helsinki [8]\u00a0and approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (Approval No.: [2015]-084\u20132).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed patient consent was not required given the retrospective nature of the study.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}